EP0804184A1 - USE OF $g(v)-GUANIDINOCARBOXYLIC ACID ESTERS - Google Patents
USE OF $g(v)-GUANIDINOCARBOXYLIC ACID ESTERSInfo
- Publication number
- EP0804184A1 EP0804184A1 EP94909036A EP94909036A EP0804184A1 EP 0804184 A1 EP0804184 A1 EP 0804184A1 EP 94909036 A EP94909036 A EP 94909036A EP 94909036 A EP94909036 A EP 94909036A EP 0804184 A1 EP0804184 A1 EP 0804184A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- enzyme inhibitors
- acid esters
- inhibitors according
- helicobacter pylori
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the use of enzyme inhibitors for the manufacture of a medicament for the treatment of Helicobacter pylori-associated diseases II of the gastrointestinal tract.
- Helicobacter pylori is a spiral gram-negative bacterium with flagella, whose natural habitat is the gastric mucosa. There it secretes a large number of enzymes that attack the gastric mucosa and are the cause of gastrititis, lesions and ulcers in the stomach and duodenum.
- enzyme inhibitors are surprisingly very suitable for the treatment of Helicobacter pylori infections and the diseases of the gastrointestinal tract induced by them.
- Protease inhibitors have proven to be particularly suitable (see also “Römpp Chemie Lexikon” Georg Thieme Verlag, Stuttgart, New York, 9th edition of the Literature collection under the keyword “proteases”; Page 3647 and 3648). Combinations of protease inhibitors and lipase inhibitors are also suitable.
- Enzyme inhibitors which inhibit a broad spectrum of enzymes are particularly suitable.
- Such inhibitors are, for example, the known ⁇ -guanidino carboxylic acid esters, such as the ⁇ -guanidino alkane carboxylic acid esters (Biochem. Biophys. Acta 242, 1971, 203-208, 268. 1972221-224 and 285, 1972, 224-234 and DE-B 2050484) and in particular the p-guanidinobenzoic acid esters (Biochem. Biophys. Acta 484, 1977, 417-422 and DE-B 25 48 886, proteinase inhibition, University Printing and Publishing House, Dr. C. Wolf & Sohn, Kunststoff, 1982).
- the known ⁇ -guanidino carboxylic acid esters such as the ⁇ -guanidino alkane carboxylic acid esters (Biochem. Biophys. Acta 242, 1971, 203-208, 268. 1972221-224 and 285, 1972, 224-234 and DE-B 2050484) and in particular the p-guanidinobenzoic acid esters (Biochem.
- nafamostat 4 - [(aminoiminomethyl) amino] benzoic acid 6- (aminoiminomethyl) -2-naphthyl esters and their salts, such as, for example, their mesylates or tosylates.
- the enzyme inhibitors are mixed with the usual fillers and auxiliaries and processed into tablets, dragées, capsules, suspensions, foams or sprays.
- Suitable fillers for the production of coated tablets, capsules or tablets are, for example, sugar alcohols such as mannitol, monosaccharides such as glucose, galactose or fructose, disaccharides such as sucrose or lactose, polysaccharides such as amylose, starch or cellulose, chemically modified polysaccharides such as methyl cellulose or Hydroxypropylmethyl cellulose or inorganic fillers such as magnesium oxide, talc or disperse silica.
- Suitable auxiliaries are, for example, the usual mold release agents, such as magnesium stearate, stearic acid or calcium behenate and, if appropriate, also flavoring agents.
- the medicaments can be formulated, for example, as described in DE-A 3404595, EP-B 0142561 or EP-B 0274498.
- Such additional active ingredients are, for example, preparations which protect the mucous membrane, such as antacids, sucralfate or bismuth, substances which inhibit gastric secretion, such as anticholinergics, antimuscarinics, prostaglandin analogs, histamine H2-receptor antagonists or benzimidazole derivatives or others
- Medications such as gastro-prokinetics, carbenoxolone sodium, succus liquiritiae, special psychotropic drugs, somatostatin analogues or simethicone, but also antifungals (tioconazole, miconazole, bifonazole, ketoconazole, clotrimazole, econazole, isoconazolitone and antiponazole trolazazolitone, fluconazolitazolitone, and fluconazolazole tritazolazolitone).
- antifungals tioconazole, miconazole, bifonazole, ketoconazole, clotrimazole, econazole, isoconazolitone and antiponazole trolazazolitone, fluconazolitazolitone, and fluconazolazole tritazolazolitone.
- Suspensions, foams and sprays are also produced in a conventional manner.
- the concentration of enzyme inhibitor in medicinal products is usually 5 to 200 mg per unit dose.
- the patient is usually administered 1 to 3 dose units per day.
- the active ingredient is mixed with lactose and corn starch in the manner familiar to the person skilled in the art and granulated with a 1-5% strength aqueous hydroxypropylmethyl cellulose solution. After drying at 30-70 ° C under vacuum, the batch is mixed with magnesium stearate, mixed for 1 to 5 minutes and pressed in the usual way.
- the core obtained in this way is then coated with an aqueous suspension of hydroxypropylmethyl cellulose, color pigment, talc and polyethylene glycol.
- an aqueous suspension of hydroxypropylmethyl cellulose, color pigment, talc and polyethylene glycol are suitable for this.
- 1 tablet contains:
- the active ingredient is mixed with the excipients in one batch and filled into bags. If necessary, it is then flavored.
- the composition is as follows: Camostate 100.00 mg
- the capsule content is dosed between the capsule shell to be welded in the usual way (e.g. Scherer method).
- This is prepared separately from the capsule content by swelling the gelatin in preserved water and glycerol, stirring the pigments and drying them in a targeted manner.
- the final composition is:
- the capsule content consists predominantly of peanut oil in which the active ingredient is suspended. Soy lecithin is added to the viscous mixture for better wetting. To protect against oxidation, 2,6-di-tert-butyl-4-methylphenol is used, which is previously dissolved in peanut oil.
- the capsule contents contain finally
- a commercially available hard gelatin capsule of a suitable size is filled with a mass which has the following composition:
- the mass is made by triturating the active ingredient with lactose and mixing with the hydrogenated castor oil and hydrocollide. Then talc and magnesium stearate are added and mixed in over 5-15 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Enzyme inhibitors are used to prepare a medicament for treating gastro-intestinal diseases associated with helicobacter pylori.
Description
VERWENDUNG VON w-GUANIDINOCARBONSAEUREESTER ZUR HERSTELLUNG EINES ARZNEI¬ MITTELSUSE OF w-GUANIDINOCARBONIC ACID ESTER FOR THE PRODUCTION OF A MEDICINAL PRODUCT
Die Erfindung betrifft die Verwendung von Enzym-Inhibitoren zur Herstellung eines Arzneimittels zur Behandlung von Helicobacter pylori assoziierten Erkrankunge-ii des Magen-Darm-Traktes.The invention relates to the use of enzyme inhibitors for the manufacture of a medicament for the treatment of Helicobacter pylori-associated diseases II of the gastrointestinal tract.
Helicobacter pylori ist ein spiraliges mit Flagellen bestücktes gramnegatives Bakterium, dessen natürlicher Lebensraum die Magenschleimhaut ist. Dorthin sondert es eine Vielzahl von Enzymen ab, die die Magenschleimhat angreifen und die Ursache für Gastrititiden, Läsionen und Ulcera im Magen und Duodenum sind.Helicobacter pylori is a spiral gram-negative bacterium with flagella, whose natural habitat is the gastric mucosa. There it secretes a large number of enzymes that attack the gastric mucosa and are the cause of gastrititis, lesions and ulcers in the stomach and duodenum.
So haben beispielsweise über 80 % der Menschen, die an chronischer Gastritis leiden eine Helicobacter pylori Infektion.For example, over 80% of people who suffer from chronic gastritis have Helicobacter pylori infection.
Da die durch Helicobacter pylori induzierte Gastritis als Risikofaktor für Zwölffinger¬ darmgeschwüre (Ulcus duodeni) gilt, ist nicht überaschend, daß , man bei 95 % aller Patienten, die an diesen Geschwüren leiden, auch eine Helicobacter pylori Infektion nachweisen kann. Ähnlich verhält es sich bei Magengeschwüren (Ulcus ventriculi); hier konnte bei 65 % aller Patienten eine Helicobacter pylori Infektion nachgewiesen werden. Nach den vorliegenden Untersuchungen ist das Risiko der mit Helicobacter pylori infizierten Menschen, an Magenkrebs zu erkranken, zwei- bis sechsmal so hoch, wie das der mcht infizierten.Since the gastritis induced by Helicobacter pylori is considered a risk factor for duodenal ulcers (duodenal ulcer), it is not surprising that, in 95% of all patients suffering from these ulcers, a Helicobacter pylori infection can also be detected. The situation is similar with gastric ulcers (ulcer ventriculi); a Helicobacter pylori infection was found in 65% of all patients. According to the available studies, the risk of people infected with Helicobacter pylori to develop stomach cancer is two to six times higher than that of those who are not infected.
Die Behandlung der Helicobacter pylori Infektionen mit Antibiotika als Monotherapie hat sich als relativ ineffektiv erwiesen, so daß man meist zu einer Kombinationstherapie aus Antibiotika (zum Beispiel Tetracyclin, Amoxycillin) Metronidazol und Wismut oder mit dem Protoneninhibitor Omeprazol übergeht, Behandlungsmethoden die nicht unproblematisch sind.Treatment of Helicobacter pylori infections with antibiotics as monotherapy has proven to be relatively ineffective, so that a combination therapy of antibiotics (for example tetracycline, amoxycillin), metronidazole and bismuth or with the proton inhibitor omeprazole is usually used, treatment methods that are not without problems.
Es wurde nun gefunden, daß sich Enzym-Inhibitoren überraschenderweise recht gut zur Behandlung von Helicobacter pylori Infektionen und den von diesen induzierten Erkrankungen des Magen-Darm-Traktes eignen.It has now been found that enzyme inhibitors are surprisingly very suitable for the treatment of Helicobacter pylori infections and the diseases of the gastrointestinal tract induced by them.
Eine Liste betreffend Publikationen zum Thema Enzym-Inhibitoren findet man beispielsweise in "Römpp Chemie Lexikon" Georg Thieme Verlag, Stuttgart, New York, 9. Auflage unter dem Stichwort "Inhibitoren" (Seite 1983 und 1984).A list of publications on the subject of enzyme inhibitors can be found, for example, in "Römpp Chemie Lexikon" Georg Thieme Verlag, Stuttgart, New York, 9th edition under the keyword "Inhibitors" (pages 1983 and 1984).
Als besonders geeignet haben sich Protease-Inhibitoren erwiesen (siehe hierzu "Römpp Chemie Lexikon" Georg Thieme Verlag, Stuttgart, New York, 9. Auflage die
Literatursammlung unter dem Stichwort "Proteasen"; Seite 3647 und 3648). Geeignet sind auch Kombinationen von Protease-Inhibitoren und Lipase-Inhibitoren.Protease inhibitors have proven to be particularly suitable (see also "Römpp Chemie Lexikon" Georg Thieme Verlag, Stuttgart, New York, 9th edition of the Literature collection under the keyword "proteases"; Page 3647 and 3648). Combinations of protease inhibitors and lipase inhibitors are also suitable.
Besonders geeignet sind solche Enzym-Inhibitoren die ein breites Spektrum von Enzymen hemmen.Enzyme inhibitors which inhibit a broad spectrum of enzymes are particularly suitable.
Derartige Inhibitoren sind beispielsweise die bekannten ω-Guanidinocarbonsäureester, wie die ω-Guanidinoalkancarbonsäureester (Biochem. Biophys. Acta 242, 1971, 203-208, 268. 1972221-224 und 285, 1972, 224-234 sowie DE-B 2050484) und insbesondere die p- Guanidinobenzoesäureester (Biochem. Biophys. Acta 484, 1977, 417-422 sowie DE-B 25 48 886, Proteinase-Inhibition, Universitätsdruckerei und Verlag, Dr. C. Wolf & Sohn, München, 1982).Such inhibitors are, for example, the known ω-guanidino carboxylic acid esters, such as the ω-guanidino alkane carboxylic acid esters (Biochem. Biophys. Acta 242, 1971, 203-208, 268. 1972221-224 and 285, 1972, 224-234 and DE-B 2050484) and in particular the p-guanidinobenzoic acid esters (Biochem. Biophys. Acta 484, 1977, 417-422 and DE-B 25 48 886, proteinase inhibition, University Printing and Publishing House, Dr. C. Wolf & Sohn, Munich, 1982).
Ein bekannter ω-Guanidinoalkancarbonsäureester ist beispielsweise das Gabexate = 4-[6- [[(Aminoiminomethyl)-amino]-l-oxo-benzoesäureethylester. Bekannte p-Guanidino- benzoesäureester sind das Camostate = 4-[[4-[(Aminoiminomethyl)-amino]-benzoyl]- oxy]-2-(dimethylamino)-2-oxoethyl-phenylessigsäureester, dessen aktiver Metabolit das FOY-251 = 4-((4-[(Aminoiminomethyl)-amino]-benzoyl]-oxy-phenylessigsäureester (CA. 102, 1984, 106774v) und das Nafamostat = 4-[(Aminoiminomethyl)-amino]-benzoesäure- 6-(aminoiminomethyl)-2-naphthylester sowie deren Salze, wie zum Beispiel deren Mesylate oder Tosylate.A well-known ω-guanidinoalkane carboxylic acid ester is, for example, the gabexate = 4- [6- [[(aminoiminomethyl) amino] -l-oxo-benzoic acid ethyl ester. Known p-guanidino-benzoic acid esters are camostate = 4 - [[4 - [(aminoiminomethyl) amino] benzoyl] - oxy] -2- (dimethylamino) -2-oxoethyl-phenylacetic acid ester, the active metabolite of which is FOY-251 = 4 - ((4 - [(aminoiminomethyl) amino] benzoyl] oxyphenylacetic acid ester (CA. 102, 1984, 106774v) and the nafamostat = 4 - [(aminoiminomethyl) amino] benzoic acid 6- (aminoiminomethyl) -2-naphthyl esters and their salts, such as, for example, their mesylates or tosylates.
Zur Herstellung der Arzneimittel werden die Enzym-Inhibitoren mit den üblichen Füllstoffen und Hilfsstoffen vermischt und zu Tabletten, Dragees, Kapseln, Suspensionen, Schäume oder Sprays verarbeitet.To produce the pharmaceuticals, the enzyme inhibitors are mixed with the usual fillers and auxiliaries and processed into tablets, dragées, capsules, suspensions, foams or sprays.
Zur Herstellung von Dragees, Kapseln oder Tabletten eignen sich als Füllstoffe beispielsweise Zuckeralkohole, wie Mannit, Monosaccharide, wie Glucose, Galactose oder Fruktose, Disaccharide, wie Saccharose oder Lactose, Polysaccharide, wie Amylose, Stärke oder Zellulose, chemisch modifizierte Polysaccharide, wie Methylzellulose oder Hydroxypropylmethylzellulose oder anorganische Füllstoffe, wie Magnesiumoxid, Talkum oder disperse Kieselsäure. Geeignete Hilfsstoffe sind beispielsweise die üblichen Formtrennmittel, wie Magnesiumstearat, Stearinsäure oder Calziumbehenat und gegebenenfalls auch Geschmackskorregentien.
Um eine gesteuerte Wirkstofffreisetzung zu erzielen, kann man die Arzneimittel beispielsweise so formulieren, wie dies der DE-A 3404595, der EP-B 0142561 oder der EP-B 0274498 beschrieben ist.Suitable fillers for the production of coated tablets, capsules or tablets are, for example, sugar alcohols such as mannitol, monosaccharides such as glucose, galactose or fructose, disaccharides such as sucrose or lactose, polysaccharides such as amylose, starch or cellulose, chemically modified polysaccharides such as methyl cellulose or Hydroxypropylmethyl cellulose or inorganic fillers such as magnesium oxide, talc or disperse silica. Suitable auxiliaries are, for example, the usual mold release agents, such as magnesium stearate, stearic acid or calcium behenate and, if appropriate, also flavoring agents. In order to achieve controlled release of the active ingredient, the medicaments can be formulated, for example, as described in DE-A 3404595, EP-B 0142561 or EP-B 0274498.
Es ist selbstverständlich auch möglich freie Kombinationen einzusetzen oderIt is of course also possible to use free combinations or
Kombinationspräparate zu bereiten, die neben den Enzym-Inhibitoren zusätzlich nochCombination preparations to prepare in addition to the enzyme inhibitors
Wirkstoffe enthalten, die üblicherweise zur Behandlung von Magen-Darm-Erkrankungen verwendet werden. Solche zusätzlichen Wirkstoffe sind beispielsweise die Schleimhaut schützenden Präparate, wie Antazida, Sucralfat oder Wismut, die gastrale Sekretion hemmende Substanzen, wie Anticholin ergika, Antimuskarinika, Prostaglandin-Analoga, Histamin-H2-Rezeptor-Antagonisten oder Benzimidazol-Derivate oder sonstigeContain active ingredients that are commonly used to treat gastrointestinal disorders. Such additional active ingredients are, for example, preparations which protect the mucous membrane, such as antacids, sucralfate or bismuth, substances which inhibit gastric secretion, such as anticholinergics, antimuscarinics, prostaglandin analogs, histamine H2-receptor antagonists or benzimidazole derivatives or others
Medikamente, wie Gastro-Prokinetika, Carbenoxolon-Natrium, Succus liquiritiae, spezielle Psychopharmaka, Somatostatin-Analoga oder Simethicon aber auch Antimykotica (Tioconazol, Miconazol, Bifonazol, Ketoconazol, Clotrimazol, Econazol, Isoconazol, Fluconazol, Itraconazol) und antiparasitäre Mittel.Medications, such as gastro-prokinetics, carbenoxolone sodium, succus liquiritiae, special psychotropic drugs, somatostatin analogues or simethicone, but also antifungals (tioconazole, miconazole, bifonazole, ketoconazole, clotrimazole, econazole, isoconazolitone and antiponazole trolazazolitone, fluconazolitazolitone, and fluconazolazole tritazolazolitone).
Die Herstellung von Suspensionen, Schäume und Sprays erfolgt ebenfalls in konventioneller Weise.Suspensions, foams and sprays are also produced in a conventional manner.
In den Arzneimitteln beträgt die Konzentration an Enzym-Inhibitor normalerweise 5 bis 200 mg pro Dosiseinheit. Üblicherweise werden dem Patienten 1 bis 3 Dosiseinheiten pro Tag verabfolgt.The concentration of enzyme inhibitor in medicinal products is usually 5 to 200 mg per unit dose. The patient is usually administered 1 to 3 dose units per day.
Die nachfolgenden Beispiele dienen zur näheren Erläuterung der Erfindung.
The following examples serve to explain the invention in more detail.
Beispiel 1example 1
FilmtablettenFilm-coated tablets
In der dem Fachmann geläufigen Weise werden der Wirkstoff mit Lactose und Maisstärke gemischt und mit einer 1 - 5%igen wäßrigen Hydroxypropylmethylcellulose-Lösung granuliert. Nach der Trocknung bei 30 - 70° C unter Vakuum wird der Ansatz mit Magnesiumstearat versetzt, 1 bis 5 Minuten gemischt und in üblicher Weise verpreßt.The active ingredient is mixed with lactose and corn starch in the manner familiar to the person skilled in the art and granulated with a 1-5% strength aqueous hydroxypropylmethyl cellulose solution. After drying at 30-70 ° C under vacuum, the batch is mixed with magnesium stearate, mixed for 1 to 5 minutes and pressed in the usual way.
Der so erhaltene Kern wird anschließend mit einer wäßrigen Suspension aus Hydroxypropylmethylcellulose, Farbpigment, Talcum und Polyethylenglykol überzogen. Geeignet hierfür sind beispielsweise Wirbelschichtcoater mit einem kontinuierlichen Lackauftrag über Sprühpistolen.The core obtained in this way is then coated with an aqueous suspension of hydroxypropylmethyl cellulose, color pigment, talc and polyethylene glycol. For example, fluidized bed coaters with a continuous coating of spray guns are suitable for this.
1 Tablette enthält:1 tablet contains:
Kern:Core:
Camostate 100,00 mgCamostate 100.00 mg
Lactose 80,00 mgLactose 80.00 mg
Maisstärke 100,00 mgCorn starch 100.00 mg
Hydroxypropylmethylcellulose 15,00 mgHydroxypropylmethyl cellulose 15.00 mg
Viskosität 5Viscosity 5
Magnesiumstearat 1,5 mgMagnesium stearate 1.5 mg
Hülle:Shell:
Hydroxypropylmethylcellulose 4,00 mgHydroxypropyl methyl cellulose 4.00 mg
Viskosität 5Viscosity 5
Polyethylenglykol 3000-6000 1,00 mgPolyethylene glycol 3000-6000 1.00 mg
Eisenoxid-Farbpigment 2,00 mgIron oxide color pigment 2.00 mg
Talcum 1,00 mgTalcum 1.00 mg
Beispiel 2Example 2
(Maeenlösliches Pulver in Beuteln")(Maize-soluble powder in bags ")
Der Wirkstoff wird mit den Hilfsstoffen in einem Ansatz gemischt und in Beutel abgefüllt. Gegebenenfalls wird anschließend aromatisiert. Die Zusammensetzung lautet wie folgt:
Camostate 100,00 mgThe active ingredient is mixed with the excipients in one batch and filled into bags. If necessary, it is then flavored. The composition is as follows: Camostate 100.00 mg
Saccharose 200,00 mgSucrose 200.00 mg
Natriumcarboxymethylcellulose 2,00 mg Polysorbat oderSodium carboxymethyl cellulose 2.00 mg polysorbate or
Polyoxyethylenstearat 1,00 mgPolyoxyethylene stearate 1.00 mg
Anisöl 0,3 mgAnise oil 0.3 mg
Beispiel 3Example 3
(WeichgelatinekapseH(Soft gelatin capsule H.
In der üblichen Weise (z.B. Scherer- Verfahren) wird der Kapselinhalt zwischen die zu verschweißende Kapselhülle dosiert. Diese wird separat vom -Kapselinhalt durch Quellen der Gelatine in konserviertem Wasser und Glycerol, verrühren der Pigmente und gezieltem Trocknen hergestellt.The capsule content is dosed between the capsule shell to be welded in the usual way (e.g. Scherer method). This is prepared separately from the capsule content by swelling the gelatin in preserved water and glycerol, stirring the pigments and drying them in a targeted manner.
Die endgültige Zusammensetzung ist:The final composition is:
Glycerol 50,00 mgGlycerol 50.00 mg
H2O 30,00 mgH 2 O 30.00 mg
Eisenoxid-Farbpigment 2,00 mgIron oxide color pigment 2.00 mg
P-Hydroxybenzoesäuremethylester- 0,5 mg propylesterP-hydroxybenzoic acid methyl ester - 0.5 mg propyl ester
Gelatine 300,00 mgGelatin 300.00 mg
Der -Kapselinhalt besteht überwiegend aus Erdnußöl, in dem der Wirkstoff suspendiert wird. Zur besseren Benetzung wird dem zähflüssigen Ansatz Soja-Lecithin zugegeben. Zum Schutz vor Oxidation dient 2,6-Di-tert.-butyl-4-methylphenol, welches zuvor in Erdnußöl gelöst wird.The capsule content consists predominantly of peanut oil in which the active ingredient is suspended. Soy lecithin is added to the viscous mixture for better wetting. To protect against oxidation, 2,6-di-tert-butyl-4-methylphenol is used, which is previously dissolved in peanut oil.
Der Kapselinhalt enthält schließlichThe capsule contents contain finally
Camostate 100,00 mgCamostate 100.00 mg
Soja-Lecithin 5,00 mgSoy Lecithin 5.00 mg
2,6-Di-tert.-butyl-4-methylphenol 0,1 mg2,6-di-tert-butyl-4-methylphenol 0.1 mg
Erdnußöl ad 800,00 mg
Beispiel 4Peanut oil ad 800.00 mg Example 4
( Retard-Hartgel ati nekapseln(Retard hard gel capsules
Eine handelsübliche Hartgelatinekapsel geeigneter Größe wird mit einer Masse befüllt, die folgende Zusammensetzung besitzt:A commercially available hard gelatin capsule of a suitable size is filled with a mass which has the following composition:
Camostate 100,00 mgCamostate 100.00 mg
Lactose 100,00 mg hydriertes Rizinusöl 50,00 mgLactose 100.00 mg hydrogenated castor oil 50.00 mg
Hydroxypropylmethylcellulose 4000 cps 100,00 mgHydroxypropylmethylcellulose 4000 cps 100.00 mg
Talkum 40,00 mgTalc 40.00 mg
Magnesiumstearat 10,00 mgMagnesium stearate 10.00 mg
Die Masse wird durch Verreiben des Wirkstoffes mit Lactose und Vermischen mit dem hydrierten Rizinusöl und Hydrokollid hergestellt. Anschließend werden Talkum und Magnesiumstearat zugegeben und über 5-15 Minuten untergemischt.
The mass is made by triturating the active ingredient with lactose and mixing with the hydrogenated castor oil and hydrocollide. Then talc and magnesium stearate are added and mixed in over 5-15 minutes.
Claims
1. Verwendung von Enzym-Inhibitoren zur Herstellung eines Arzneimittels zur Behandlung von Helicobacter pylori assoziierten Erkrankungen des Magen-Darm- Traktes.1. Use of enzyme inhibitors for the manufacture of a medicament for the treatment of Helicobacter pylori-associated diseases of the gastrointestinal tract.
2. Verwendung von Enzym-Inhibitoren gemäß Patentanspruch 1, dadurch gekennzeichnet, daß diese Protease-Inhibitoren sind.2. Use of enzyme inhibitors according to claim 1, characterized in that these are protease inhibitors.
3. Verwendung von Enzym-Inhibitoren gemäß Patentanspruch 2, dadurch gekennzeichnet, daß diese ω-Guanidinocarbonsäureester sind.3. Use of enzyme inhibitors according to claim 2, characterized in that these are ω-guanidinocarboxylic acid esters.
4. Verwendung von Enzym-Inhibitoren gemäß Patentanspruch 3, dadurch gekennzeichnet, daß diese p-Guanidinobenzoesäureester oder ε -Guanidinocapronsäureester sind.4. Use of enzyme inhibitors according to claim 3, characterized in that these are p-guanidinobenzoic acid esters or ε-guanidinocaproic acid esters.
5. Verwendung von Enzym-Inhibitoren gemäß Patentanspruch 4, dadurch gekennzeichnet, daß diese Camostate, Naphamostate, FOY-251 und/oder Gabexate und deren Salze sind.5. Use of enzyme inhibitors according to claim 4, characterized in that these are Camostate, Naphamostate, FOY-251 and / or Gabexate and their salts.
6. Verwendung von Enzym-Inhibitoren gemäß Patentanspruch 1 bis 5, dadurch gekenn¬ zeichnet, daß das hergestellte Arzneimittel zusätzlich noch Wirkstoffe enthält, die üblicherweise zur Behandlung von Magen-D arm-Erkrankungen verwendet werden. 6. Use of enzyme inhibitors according to claim 1 to 5, characterized gekenn¬ characterized in that the medicinal product additionally contains active ingredients which are usually used for the treatment of gastrointestinal diseases.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4305536 | 1993-02-19 | ||
DE4305536A DE4305536A1 (en) | 1993-02-19 | 1993-02-19 | Use of enzyme inhibitors for the manufacture of a medicament |
PCT/EP1994/000523 WO1994018964A1 (en) | 1993-02-19 | 1994-02-18 | USE OF φ-GUANIDINOCARBOXYLIC ACID ESTERS |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0804184A1 true EP0804184A1 (en) | 1997-11-05 |
Family
ID=6481132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94909036A Withdrawn EP0804184A1 (en) | 1993-02-19 | 1994-02-18 | USE OF $g(v)-GUANIDINOCARBOXYLIC ACID ESTERS |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0804184A1 (en) |
JP (1) | JP2002515002A (en) |
AU (1) | AU6205394A (en) |
DE (1) | DE4305536A1 (en) |
WO (1) | WO1994018964A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2004678A1 (en) * | 2006-03-15 | 2008-12-24 | Csir | Modulation of glutamine synthetase activity |
GB0808690D0 (en) * | 2007-05-17 | 2008-06-18 | Serentis Ltd | Therapeutic use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5775922A (en) * | 1980-10-29 | 1982-05-12 | Nippon Chemiphar Co Ltd | Novel remedy for peptic ulcer |
JPS6229566A (en) * | 1985-07-30 | 1987-02-07 | Taiyo Yakuhin Kogyo Kk | Novel guanidinomthylbenzoic acid derivative |
JPS63126860A (en) * | 1986-11-17 | 1988-05-30 | Nippon Haipotsukusu:Kk | Guanidinomethylbenzoic acid derivative |
JPS63218652A (en) * | 1987-03-09 | 1988-09-12 | Taiyo Yakuhin Kogyo Kk | Novel guanidinomethylbenzoic acid derivative and remedy for peptic ulcer containing said derivative |
JPH04217950A (en) * | 1990-03-28 | 1992-08-07 | Asahi Chem Ind Co Ltd | Hydroxamic acid derivative, enzyme inhibitor and antiulcer agent |
-
1993
- 1993-02-19 DE DE4305536A patent/DE4305536A1/en not_active Withdrawn
-
1994
- 1994-02-18 WO PCT/EP1994/000523 patent/WO1994018964A1/en not_active Application Discontinuation
- 1994-02-18 AU AU62053/94A patent/AU6205394A/en not_active Abandoned
- 1994-02-18 EP EP94909036A patent/EP0804184A1/en not_active Withdrawn
- 1994-02-18 JP JP51867094A patent/JP2002515002A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9418964A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994018964A1 (en) | 1994-09-01 |
AU6205394A (en) | 1994-09-14 |
DE4305536A1 (en) | 1994-08-25 |
JP2002515002A (en) | 2002-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3309516C2 (en) | ||
DE69331948T2 (en) | PLEASANT TASTING PHARMACEUTICAL COMPOSITIONS | |
DE69217191T2 (en) | MULTIPARTICLE TABLET WITH QUICK RESOLUTION | |
DE69820287T2 (en) | Pharmaceutical preparation comprising chlodronate as the active ingredient and silicified microcrystalline cellulose as the excipient | |
DE69213800T2 (en) | Oral gastric juice-stable drugs with controlled release of active ingredients containing bile acids and their salts | |
DE2332484C2 (en) | Drugs with delayed release of active substances | |
CA1333998C (en) | Cholesterol-lowering combination compositions of niacin and magnesium salt | |
EP1086701B1 (en) | Simethicone containing laxative composition | |
DE2551280A1 (en) | L-DOPA PREPARATION | |
KR100479968B1 (en) | Use of gastrointestinal lipase inhibitors | |
DE69530759T2 (en) | FILM COATED TABLET CONTAINING PARACETAMOL AND DOMPERIDONE | |
CN109893516A (en) | For treating the pharmaceutical composition of helicobacter pylori | |
US5310560A (en) | Medicine for the treatment of illnesses of the respiratory organs | |
EP1315481B1 (en) | Medicament for treating intestinal diseases | |
KR100238565B1 (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
US20080038336A1 (en) | Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent | |
CA2132427A1 (en) | Method and composition for suppresion of side effects of anti-inflammatory drugs | |
DE602004009079T2 (en) | CARBOSTYRIL DERIVATIVES FOR ACCELERATED SPOKEN SPECIALTY | |
WO1995020383A1 (en) | Modified-release metronidazole compositions and methods for making and using same | |
EP1480626A1 (en) | Ambroxol for treating painful conditions in the mouth and pharyngeal cavity | |
JPH07242560A (en) | Antimicrobial | |
EP0804184A1 (en) | USE OF $g(v)-GUANIDINOCARBOXYLIC ACID ESTERS | |
JPH0656677A (en) | Antacid composition | |
EP0301373B1 (en) | Products containing gallopamil and prazosine | |
US5294440A (en) | Composition for treatment of cold sores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951123 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
RTI1 | Title (correction) |
Free format text: USE OF OMEGA-GUANIDINOCARBOXYLIC ACID ESTERS |
|
17Q | First examination report despatched |
Effective date: 19991229 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000509 |